Eric Assénat
Impact in
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.1%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
Papers in
- Hepatology 79
- Hepatocellular Carcinoma Treatment and Prognosis 73
- Oncology 84
- Colorectal Cancer Treatments and Studies 26
- Pancreatic and Hepatic Oncology Research 20
- Colorectal Cancer Surgical Treatments 10
- Co-authors
- Marc Ychou (41 shared papers)Rosine Guimbaud (9 shared papers)Jean‐Luc Raoul (3 shared papers)Françoise Desseigne (7 shared papers)Olivier Bouché (5 shared papers)Christelle de la Fouchardière (6 shared papers)Michel Pierre Ducreux (5 shared papers)Jean‐Baptiste Bachet (2 shared papers)
- Journals
- Annals of Oncology (27 papers)Journal of Hepatology (11 papers)Cancers (10 papers)The Lancet Oncology (8 papers)Digestive and Liver Disease (8 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Eric Assénat
209 papers receiving 21.5k citations
Eric Assénat's Hit Papers
Peers
Comparison fields: 5 of 129
- Hepatology 6.1k
- Oncology 10k
- Internal Medicine 510
- Cancer Research 1k
- Surgery 2k
Countries citing papers authored by Eric Assénat
This map shows the geographic impact of Eric Assénat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Assénat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Assénat more than expected).
Fields of papers citing papers by Eric Assénat
This network shows the impact of papers produced by Eric Assénat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Assénat. The network helps show where Eric Assénat may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Assénat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 221 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer Hit paper breakdown → | 2011 | 6279 |
| 2 | FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Hit paper breakdown → | 2018 | 2184 |
| 3 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 1397 |
| 4 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial Hit paper breakdown → | 2021 | 890 |
| 5 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial Hit paper breakdown → | 2022 | 821 |
| 6 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 728 |
| 7 | Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial Hit paper breakdown → | 2017 | 663 |
| 8 | Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study Hit paper breakdown → | 2013 | 517 |
| 9 | Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib Hit paper breakdown → | 2014 | 500 |
| 10 | 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer Hit paper breakdown → | 2019 | 489 |
| 11 | Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial Hit paper breakdown → | 2020 | 467 |
| 12 | Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study Hit paper breakdown → | 2019 | 410 |
| 13 | Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial Hit paper breakdown → | 2014 | 337 |
| 14 | 2015 | 318 | |
| 15 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study Hit paper breakdown → | 2018 | 308 |
| 16 | Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Hit paper breakdown → | 2024 | 239 |
| 17 | Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Hit paper breakdown → | 2022 | 225 |
| 18 | 2019 | 214 | |
| 19 | 2017 | 195 | |
| 20 | Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2023 | 189 |
About Eric Assénat
Eric Assénat is a scholar working on Hepatology, Oncology, Surgery, Pharmacology and Cancer Research, having authored 221 papers that have together received 21.9k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (73 papers), Colorectal Cancer Treatments and Studies (26 papers), Pancreatic and Hepatic Oncology Research (20 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers), Colorectal Cancer Surgical Treatments (10 papers), Pharmacogenetics and Drug Metabolism (9 papers), Neuroendocrine Tumor Research Advances (9 papers) and Cancer Genomics and Diagnostics (9 papers). The work is most often cited by research in Hepatology (6.1k citations), Oncology (10k citations), Internal Medicine (510 citations), Cancer Research (1k citations) and Surgery (2k citations). Eric Assénat has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Marc Ychou, Rosine Guimbaud, Jean‐Luc Raoul, Françoise Desseigne, Olivier Bouché, Christelle de la Fouchardière, Michel Pierre Ducreux, Jean‐Baptiste Bachet, Y. Bécouarn and Antoine Adenis. Their work appears in journals such as Annals of Oncology, Journal of Hepatology, Cancers, The Lancet Oncology and Digestive and Liver Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.